Summit Therapeutics Inc.
SMMT
$17.34
-$1.57-8.30%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -61.20M | -56.25M | -60.39M | -43.47M | -36.57M |
| Total Depreciation and Amortization | 22.00K | 20.00K | 20.00K | 27.00K | 30.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.19M | 16.97M | 24.36M | 9.11M | 8.51M |
| Change in Net Operating Assets | -686.00K | 8.96M | 3.00M | 4.20M | 8.57M |
| Cash from Operations | -48.67M | -30.30M | -33.00M | -30.13M | -19.46M |
| Capital Expenditure | -14.00K | -58.00K | -63.00K | -4.00K | -2.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 83.50M | -108.56M | -200.02M | 19.88M | 60.57M |
| Cash from Investing | 83.48M | -108.62M | -200.08M | 19.87M | 60.57M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -24.50M | -75.50M | -- | -- | 0.00 |
| Issuance of Common Stock | 888.00K | 279.64M | 200.21M | 485.00K | 6.87M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -619.00K |
| Cash from Financing | -23.61M | 204.14M | 200.21M | 485.00K | 6.25M |
| Foreign Exchange rate Adjustments | -108.00K | 114.00K | 12.00K | -36.00K | 272.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.09M | 65.34M | -32.86M | -9.81M | 47.63M |
